Neoadjuvant chemotherapy with Bevacizumab

Primary objectives: Assessment of the efficacy of the combination of Bevacizumab with irinotecan- based chemotherapy (FOLFIRI) or oral capecitabine (XELIRI) in terms of resectability of the primary non-resectable liver metastases from metastatic colorectal cancer.
Primary endpoints: Assessment of effect of neoadjuvant combination of FOLFIRI or XELIRI chemotherapy regimen and bevacizumab on the resectability of liver metastases initially assessed as unresectable.